The CALGB is comprised of 26 academic medical centers and over 200 affiliated community hospitals joined in the pursuit of improved cancer treatment and better understanding of tumor biology and cancer treatment outcomes via the conduct of controlled clinical trials. Over 4,000 members of the Group including oncology physicians, radiologists, pathologists, statisticians, clinical research associates, oncology nurses, pharmacists, health outcomes researchers, and basic scientists participate in these studies. From 25-30 Phase III protocols are active at any one time, along with phase II and phase I studies that provide preliminary data required for the appropriate design of large scale randomized trials. Multidisciplinary disease committees of the Group design and implement protocols for the treatment of patients with leukemia, lymphoma, breast, respiratory, Gl and GU cancer. Modality committees, including Leukemia Correlative Sciences, Imaging, Pharmacology and Experimental Therapeutics, Surgery, Transplant, Cancer in the Elderly, Cancer Control and Health Outcomes, and Oncology Nursing provide expertise that enhances the contribution of these disciplines to CALGB studies. Scientific resources committees, including Clinical Research Associates, Pathology and Radiation Oncology, provide essential quality assurance and training activities for the Group. Major areas of emphasis in CALGB include development of innovative treatments for patients with cancer;studies of molecular predictors of prognosis and response to therapy;studies of the pharmacokinetics, pharmacodynamics and pharmacogenetics of new and established anticancer drugs;evaluation of minimally invasive surgical techniques and novel imaging technologies;determining the cost and cost-effectiveness of new cancer therapies;evaluating the impact of cancer and its treatment on the quality of life of cancer patients and their caregivers;developing new strategies for cancer prevention;and addressing the needs of special populations, particularly minorities and the elderly. A new core facility in cancer imaging was established to provide central review and archiving of PET and CT images and to set standards for image acquisition and transmission at CALGB institutions. Three established biorepositories collect, archive and distribute frozen and paraffin-embedded solid tumor tissues, leukemia cells, plasma, serum, urine and DNA for correlative science studies.
CALGB is a national cancer clinical trials group that aims to develop improved cancer treatments, determine the patient subsets most likely to benefit from those treatments and understand the impact of cancer and its treatment on patients, their caregivers and society as a whole. CALGB has contributed to improvements in public health in a number of ways including conducting trials that have resulted in FDA approval of new drugs developing more effective chemotherapy regimens and identifying biological subsets of patients who are most likely to benefit or experience toxicity from specific cancer treatments. Through our work to individualize cancer treatment we also aim to reduce the costs of cancer care to individual patients and the healthcare system.
|Shiovitz, Stacey; Bertagnolli, Monica M; Renfro, Lindsay A et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637-45|
|Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10|
|Parsons, J Kellogg; Pierce, John P; Natarajan, Loki et al. (2013) A randomized pilot trial of dietary modification for the chemoprevention of noninvasive bladder cancer: the dietary intervention in bladder cancer study. Cancer Prev Res (Phila) 6:971-8|
|Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43|
|Edelman, Martin J; Hodgson, Lydia; Rosenblatt, Paula Y et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7:649-54|
|Edelman, Martin J; Hodgson, Lydia; Wang, Xiaofei et al. (2011) Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol 6:1902-6|
|Harrop, J Phil; Dean, Julie A; Paskett, Electra D (2011) Cancer survivorship research: a review of the literature and summary of current NCI-designated cancer center projects. Cancer Epidemiol Biomarkers Prev 20:2042-7|
|Dragnev, Konstantin H; Ma, Tian; Cyrus, Jobin et al. (2011) Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) 4:818-28|
|Garber, Judy E; Halabi, Susan; Tolaney, Sara M et al. (2010) Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 102:942-9|
|Yee, Lisa D; Lester, Joanne L; Cole, Rachel M et al. (2010) Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. Am J Clin Nutr 91:1185-94|
Showing the most recent 10 out of 20 publications